The Canada-U.S. Trade War Is a Wake-Up Call for Pharmaceutical Manufacturing
Canada’s trade relationship with the United States is entering a period of significant uncertainty. New tariffs, countermeasures, and shifting trade policies are changing the environment in which Canadian businesses operate, invest, and plan for the future.
For Canada’s pharmaceutical manufacturing sector, these developments raise a bigger question: How do we ensure Canada has the pharmaceutical manufacturing capacity it needs when the rules of trade can change so quickly?
That uncertainty is particularly significant for the pharmaceutical sector. On September 29, new U.S. tariffs under Section 232 of the Trade Expansion Act took effect for certain patented pharmaceutical products and associated ingredients imported into the United States. The measures establish a tariff rate of up to 100%, subject to a number of exemptions, reduced rates and company-specific agreements. Generic pharmaceuticals and their associated ingredients are not subject to the Section 232 tariffs at this time.
While the full impact of these measures remains to be seen, they demonstrate how quickly the conditions surrounding pharmaceutical trade can change. For a highly integrated industry with complex international supply chains, uncertainty around tariffs, market access and future trade policy can influence where companies invest, manufacture and build capacity.
The current trade environment is a reminder that Canada cannot take access to international markets, stable supply chains, or domestic manufacturing capacity for granted. While Canada cannot control every decision made by its trading partners, it can control how it strengthens its own pharmaceutical manufacturing foundation.
Trade Policy Can Change Quickly. Manufacturing Capacity Cannot.
Tariffs can be introduced or changed relatively quickly. Pharmaceutical manufacturing works on a very different timeline.
Building and expanding manufacturing facilities requires significant capital and long-term planning. Developing a skilled workforce takes time. Establishing reliable supply chains, meeting regulatory requirements, and creating the conditions for sustainable production can take years.
That means Canada cannot wait until a trade disruption occurs to begin thinking about domestic capacity.
Pharmaceutical manufacturing requires long-term investment, and greater trade uncertainty makes policies that give manufacturers confidence to continue investing and producing in Canada increasingly important.
The decisions being made today will help determine what Canada is capable of producing five, ten, and twenty years from now.
The Trade War Changes the Manufacturing Equation
For decades, Canada and the United States have benefited from deeply integrated supply chains and a close trading relationship. But an increasingly protectionist trade environment creates new considerations for companies deciding where to invest and manufacture.
When tariffs, market access, or other trade barriers change, businesses have to respond. Investment decisions can change. Supply chains can shift. Production may move closer to major markets.
Canadian pharmaceutical manufacturers need an environment that makes it viable to build, produce, invest, and grow here. If other countries are actively creating incentives and policies designed to attract or reshore pharmaceutical production, Canada must ensure that it remains a competitive place to manufacture medicines.
Canada now faces a choice: allow changing global conditions to determine where pharmaceutical manufacturing happens, or create conditions that encourage companies to manufacture and invest here.
Pharmaceutical Manufacturing Is Part of Canada's Critical Infrastructure
The trade conflict also reinforces an important point: pharmaceutical manufacturing is not simply another industrial sector. It is part of the infrastructure that supports Canada’s healthcare system.
When Canadians need essential medicines, the ability to manufacture more of those medicines domestically provides an additional layer of resilience when international trade or supply chains are disrupted.
Canada already has generic and contract pharmaceutical manufacturers producing medicines here. The challenge is to strengthen that foundation and create the conditions that allow those manufacturers to remain competitive, expand capacity, and continue investing in Canada.
And the benefits extend beyond the medicines themselves. Pharmaceutical manufacturing supports skilled workers, quality specialists, engineers, logistics providers, suppliers, and communities across the country.
Maintaining domestic capacity is therefore both a healthcare and economic priority.
Canada Cannot Control Every Tariff, But It Can Strengthen Its Own Foundation.
The direction of U.S. trade policy is ultimately outside Canada’s control. What Canada can control is the environment it creates for pharmaceutical manufacturing at home.
That means asking whether Canadian policies encourage companies to manufacture here. It means examining whether procurement decisions recognize the strategic value of domestic production. It means creating a predictable regulatory and policy environment that gives manufacturers confidence to make long-term investments.
And it means recognizing pharmaceutical manufacturing as a strategic national capability rather than something that can simply be rebuilt when it is suddenly needed.
The current trade environment reinforces the importance of focusing on those areas Canada can influence. Strengthening domestic pharmaceutical manufacturing is one of the most tangible ways Canada can improve its long-term healthcare and economic resilience.
Canada cannot control every development beyond its borders. But it can make sure that when the global environment changes, we have the capacity, infrastructure, and manufacturers at home to respond.
The Canadian Pharmaceutical Manufacturers and Exporters Alliance (CPMEA) – Alliance fabricants et exportateurs pharmaceutiques du Canada (AFEPC) represents pharmaceutical companies that manufacture in Canada. We have come together in an Alliance to tell the story of drug production in Canada and to raise awareness of the unique issues facing our industry.
Click here to contact us, or email us directly at info@cpmea.ca.
